BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$2.56 +0.36 (+16.36%)
At close: Nov 11, 2026 · 4:00 PM EST

BridgeBio Oncology Therapeutics (BBOT) Non-Current Deferred Revenue (2025)

Updated

BridgeBio Oncology Therapeutics (BBOT) recorded Non-Current Deffered Revenue of $5.52 million in Q2 2025, unchanged from $5.52 million a year earlier and unchanged from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Non-Current Deferred Revenue (2025) Analysis & Trends

Starting with Q2 2024, BridgeBio Oncology Therapeutics' Non-Current Deffered Revenue history includes 5 quarters.

  • Per Business Quant, the preceding three quarters came in at $5.52 million (Q1 2025), $5.52 million (Q4 2024) and $5.52 million (Q3 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 BridgeBio Oncology Therapeutics 176.55 Mn -920.76 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 5.52 Mn
API Access

BridgeBio Oncology Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=BBOT&period=max&api_key=YOUR_API_KEY